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Abstract 
The aim of this research was to assess the agreement between the distribution of technetium-99m macroaggregated 
albumin (MAA) and yttrium-90 microspheres in radioembolization of the liver, as well as the correspondence between the 
desired radiation dose and the true radiation dose in the target area. 
Materials and Methods: The relative distribution of yttrium-90 microspheres was estimated in 5 patients, using the activity 
distributions from technetium-99m MAA SPECT/CT and yttrium-90 PET/CT imaging.  
A Monte Carlo simulation using these relative activity distributions was used to calculate the radiation dose to the liver.  
Results and Discussion: A large difference in radiation dose was found when comparing technetium-99m MAA and yttrium-
90 microspheres distributions. In addition, the distribution of yttrium-90 microspheres in the liver, obtained from the PET 
images, was highly inhomogeneous. 
Relative technetium-99m MAA distribution does not necessarily comply with the distribution of yttrium-90 microspheres. 
Therefore, technetium-99m MAA scans cannot directly be used for prospective radiation dose assessment. Due to the 
inhomogeneity of the distribution of yttrium-90 microspheres, the estimated radiation dose in large parts of the targeted 
lobe(s) is smaller than the desired radiation dose.  
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Introduction 
Between 1990 and 2015, liver cancer was the 6th most common cancer worldwide in terms of incidence and the 4th most 
common leading cause of mortality. In 2015 the global number of incident cases was estimated at 854.000, the number of 
deaths just slightly lower (810.000) [1]. The most prevalent type of primary liver cancer is hepatocellular carcinoma (HCC). 
Depending on the staging of HCC, several treatments including liver transplantation, hepatic resection, ablation, transhepatic 
artery chemoembolization (TACE) and radioembolization with yttrium-90 microspheres are available [2]. This article focuses 
on the latter.  
The objective of the study was to assess the correspondence between the dose distribution calculated based on technetium-
99m macroaggregated albumin (MAA) single photon emission computed tomography (SPECT) and yttrium-90 microspheres 
positron emission tomography (PET) based images, as well as the correspondence between the desired dose and the true 
dose in the target area. 
Radioembolization with yttrium-90 microspheres 
The first report of treatment of hepatic cancer with intraarterial infusion of yttrium-90 microspheres originates from the 
1960s [3]. In the following decades, patients with HCC included in several studies were treated with yttrium-90 microspheres 
[4-6]. Triggered by the results of this palliative treatment an optimal radiation dose to the tumor was investigated, which 
was found to be > 120 Gy [7]. 
The amount of yttrium-90 activity needed to achieve the desired radiation dose can be calculated by the following formula 
(1). 
𝐴90𝑌 =
𝐷∙𝑚𝑙
𝐶∙(1−𝐹)
       (1) 
With A90Y the administered activity of yttrium-90 microspheres in GBq, D the desired dose to the target volume in Gy, ml the 
mass of the target volume in kg and F the lung shunt fraction (LSF), the estimated amount of administered activity shunting 
to the lungs. The factor C in the denominator, with a value of 49.8 J GBq-1, is a conversion factor reflecting the average 
deposited energy per GBq of administered yttrium-90 activity. It needs to be pointed out that (1) is a simplified view on 
reality, as it calculates the activity needed for a homogeneous dose distribution in a target volume with dimensions much 
larger than the yttrium-90 maximum beta range of approximately one centimeter in soft tissue. 
Yttrium-90 decays almost exclusively (>99.9%) to zirconium-90 by emitting an electron with an average energy of 933.7 keV 
[8], but in addition 32 ppm of yttrium-90 decay yields emission of a positron [9]. Because of the different decay paths, the 
assessment of the distribution of yttrium-90 microspheres after administration can be done by performing either a 
SPECT/Computed Tomography (CT) scan or a PET/CT scan [10-11]. Using PET rather than bremsstrahlung SPECT for 
assessment of the yttrium-90 distribution provides images with higher image quality, because of the higher spatial resolution 
of PET imaging [12]. 
Dosimetry 
When estimating the amount of yttrium-90 activity needed for radioembolization, a homogeneous radiation dose 
distribution in the target volume is assumed. The true dose distribution, however, depends on the distribution of the yttrium-
90 microspheres in the liver, and may be of interest, as a relationship between tumor dose and response is suggested [13-
16]. Real-time assessment of the distribution of yttrium-90 microspheres during administration is currently not feasible. 
Therefore, post-administration imaging is used to estimate the dose distribution. 
To prevent the lungs from receiving an intolerable high dose, excessive shunting from the liver to the lungs or to the 
abdominal structures should be ruled out before treating a patient with yttrium-90 microspheres. Therefore, a scout dose 
technetium-99m MAA is administered two weeks before the yttrium-90 administration by infusion in the hepatic artery and 
subsequently imaged using Whole Body (WB) imaging on a SPECT/CT scanner. CT imaging can be appended to the study 
for both anatomical correlation and attenuation correction. The LSF can be estimated from the WB images. 
Prospective dosimetry uses the technetium-99m MAA SPECT/CT scan as the expected distribution of yttrium-90 
microspheres. Dose estimation can be performed by quantitative SPECT, evaluating the ratio of counts in different volumes 
of interest [17].  
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Patients with a low LSF are eligible for administration of yttrium-90 microspheres. The total lung dose must not exceed 30 
Gy. Similar to technetium-99m MAA, administration takes place by infusion in the hepatic artery. Subsequently, the 
distribution of the microspheres can be assessed by PET/CT imaging. Acquired images can be used for patient specific 
retrospective dosimetry. As retrospective dosimetry is based on the true distribution of the microspheres, it will yield a 
reliable dose distribution when properly imaged. Phantom measurements showed that accurate dosimetry may be indeed 
provided using this method [10]. 
Methods 
A. Selective internal radiation therapy (SIRT) 
Five patients included in this retrospective study were treated with TheraSphere yttrium-90 glass microspheres (Nordion Inc., 
Ottawa, Canada) at the Department of Radiology & Nuclear Medicine at the VU University Medical Center, Amsterdam.  
Patients with HCC were candidates for the procedure. The target volume was calculated by the radiologist through manual 
delineation of the contour on a diagnostic CT scan. For patients with multiple targets, multiple target volumes were retrieved. 
The mass of the target volume was obtained by multiplication of the target volume with the density of 1.03 g/ml. All 
administrations of both technetium-99m MAA and yttrium-90 microspheres were performed by the same experienced 
interventional radiologist under fluoroscopy (Philips Allura X FD20 (Philips Healthcare, Eindhoven, The Netherlands)) set to 
auto exposure. In each procedure, the catheter tip was positioned carefully to ensure technetium-99m MAA and yttrium-90 
microspheres were administrated from an identical position, see Figure 1. 
 
Figure 1 Identical placement of the catheter tip for administration of technetium-99m MAA (left) and yttrium-90 
microspheres (right) two weeks after the administration of technetium-99m MAA. The coil in the lower mid part of both 
images, placed because of collateral vasculature nearby the tumor, is clearly visible and can be used as a reference.  
Suitability for radioembolization with yttrium-90 microspheres was assessed for selected patients by performing a SPECT/CT 
scan. 100 MBq technetium-99m MAA was administered intravenously. 1 to 4 hours after administration, the patient was 
scanned using a dual-head Siemens Symbia T2 scanner, (Siemens AG, Erlangen, Germany).  
Whole body imaging was performed from head to groin, with a bed speed of 12 cm/min, for on average 15 min. For the 
lung volume, a trapezium was used (as shown in Figure 2).  The LSF was defined as the ratio between lung counts and whole 
body counts. A LSF of less than 5% was considered safe for yttrium-90 administration. 
SPECT/CT data was acquired using a step and shoot method, covering 360 degrees in 32 steps of 40 seconds each. A standard 
technetium-99m energy window (129 – 150 keV) was used. For anatomical reference, a low dose CT scan with 5 mm slice 
thickness and 1.27 mm × 1.27 mm pixels was acquired.  
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Figure 2 Definition of the lung ROI for evaluation of the LSF, shown in addition to the liver area. The liver is delineated using 
a threshold of 20% of the maximum number of counts per voxel. 
Clinically used reconstructions were obtained using Filtered Back Projection (FBP). A generalized Hanning filter with cut-off 
set at 0.9 times the Nyquist frequency and a steepness factor of 0.5 was applied. Reconstructed slices had a thickness of 4.8 
mm, and a pixel size of approximately 5 × 5 mm2. For the purpose of this study, an additional attenuation corrected iterative 
reconstruction was generated. 
Similar to the technetium-99m MAA, the yttrium-90 microspheres were administered under fluoroscopy. Administered 
yttrium-90 activity ranged from 1.5 to 5.1 GBq. After administration, a PET/CT scan was acquired using a Philips Ingenuity TF 
PET/CT scanner (Philips Healthcare, Eindhoven, The Netherlands). Patients were scanned for 20 minutes (two bed positions 
of 10 minutes each). A helical low dose CT scan was performed for anatomical correlation and attenuation correction. Pixels 
of 1.17 mm × 1.17 mm with a slice width of 5 mm were chosen. For the PET reconstructions, a method compliant with the 
EARL criteria [18] was used. The BLOB-OS-TF reconstruction algorithm without point spread function (PSF) modelling was 
performed [19]. Reconstructions were made using 4 × 4 × 4 mm3 voxels and a 144 × 144 matrix, and in addition to CT-based 
attenuation correction, scatter correction and randoms correction was applied. 
 B. Computational 
Assessment of the dose distribution inherent to the distribution of yttrium-90 microspheres was performed using the Geant4 
Application for Tomographic Emission (GATE) [18]. GATE is an open source software package suitable for performing Monte 
Carlo based simulation, developed specifically for computations related to medical applications. Dose distributions were 
simulated using a geometry (the patient, represented by a CT scan), a source (the activity distribution in the patient, 
represented by a SPECT or PET scan) and a set of simulation parameters describing the behavior of emitted particles (the 
physics). 
The types of tissue that an electron encounters on its path have impact on the location of deposition of its energy. In tissue 
with lower density, for example, an electron will lose less energy per unit length, and will therefore travel further. Using the 
CT scans acquired in SPECT/CT and PET/CT imaging, a patient-specific 3D map of material properties and atomic cross-
sections was constructed. First, the Hounsfield Units (HU) were converted to different types of tissue using the method 
proposed by Schneider et al. [21]. Subsequently, the atomic compositions and density of these types of tissue were imported. 
For tissues that cover a large range of HU such as lung tissue, the compositions were specified in multiple intervals. The 
compositions were used to specify the cross sections.  
To calculate the dose distribution based on the SPECT/CT scan, the assumption was made that the distribution of the 
technetium-99m MAA corresponds with the distribution of the yttrium-90 microspheres.  As only a minor fraction of decays 
involves emitting a positron, the dose distribution can be closely approximated by only monitoring the emitted electrons. In 
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the simulation, 1∙107 decay events are considered. The probability of a single event occurring in a voxel is linearly dependent 
on the number of counts in that voxel.  
Each event leads to production of an electron with an initial energy E, which is also drawn from the probability distribution 
based on the energy spectrum [22]. Isotropic emission of electrons is assumed. 
Regarding yttrium-90 as a pure beta-emitter, initially only electrons are produced. Interaction processes incorporated in the 
simulation include the photo-electric effect, 
Compton and Rayleigh scattering, ionization and creation of bremsstrahlung. Secondary particles created in these processes 
are also tracked, and can contribute to the radiation dose. To avoid infrared divergence and thus limit computational costs, 
the secondary particles from electrons with an energy below 10 keV are not created. Deposited energy per voxel was 
monitored, and converted to radiation dose using the local density and voxel dimensions. To calculate the dose (as shown 
in Figure 3), the calculated radiation dose was scaled by the ratio between the total number of events in the patient N, 
calculated by equation (2), and the number of events considered in the Monte Carlo simulation. 
𝑁 =  𝐴0 ∫ 𝑒
−𝜆𝑡𝑑𝑡 
∞
0
      (2) 
With A0 the administered yttrium-90 activity and λ = 3∙10-6 s-1 [8] the decay constant. Due to the low positron yield, the PET 
images exhibited a high background level. Therefore, a background correction was applied. Additionally, both SPECT and 
PET dose images were smoothed by averaging each voxel with its neighbors (26-connectivity). 
 
Figure 3 Visualization of the radiation dose distributions, calculated by Monte Carlo simulation based on technetium-99m 
MAA SPECT images (a) and yttrium-90 microspheres PET images (b). Notice that the PET-based dose distribution is less 
homogeneous, and also that the relative intensities in SPECT- and PET-based dose distributions are not similar.  
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Results 
The dose distributions resulting from the technetium-99m MAA SPECT/CT scan and the yttrium-90 PET/CT scan were 
compared for each patient. Radiation dose profile characteristics were assessed (maximum local radiation dose, volume 
receiving a dose higher than a specified dose) and dose volume histograms (DVHs) were obtained.  
Table 1 Maximum dose in a single voxel from dosimetry based on SPECT and PET imaging. Injected activity is determined 
by applying equation (1). 
 Desired 
dose (Gy) 
Yttrium-
90 activity 
(GBq) 
Target mass 
(kg) 
‘Rule of 
thumb’ 
dose (Gy) 
SPECT PET 
Maximum 
dose (Gy) 
Maximum 
dose (Gy) 
Patient 1 120 3.78 1.483 127.4 786 294 
Patient 2 100 2.29 1.099 104.2 383 243 
Patient 3 120 8.34 3.197 130.5 209 434 
Patient 4 120 3.80 1.547 123.7 345 237 
Patient 5 120 4.42 1.773 125.0 451 374 
Table 1 shows the parameters used for planning the procedure, as well as the maximum radiation dose calculated using the 
SPECT and PET images. The ‘rule of thumb’ dose is calculated under assumption of a homogeneous distribution of the 
administered yttrium-90 in the target volume. The maximum radiation dose shows differences between SPECT- and PET-
based dosimetry ranging up to a factor two. The maximum radiation dose is larger than the ‘rule of thumb’ dose in all 
patients. 
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Table 2 Comparison of volumes receiving a radiation dose of at least the shown threshold value, determined by PET-based 
SPECT-based dosimetry.  
Patient Desired 
dose 
(Gy) 
Target 
volume 
(cm3) 
Volume receiving a radiation dose (cm3) 
> 60 Gy > 80 Gy > 100 Gy > 120 Gy 
PET SPECT PET SPECT PET SPECT PET SPECT 
1 120 1339 877 720 502 601 314 516 192 448 
2 100 1037 71 596 30 307 14 145 7 72 
3 120 3016 2065 1750 1370 1135 850 788 486 402 
4 120 1459 344 530 197 294 125 146 78 83 
5 120 1673 493 1353 209 844 119 449 73 247 
In Table 2 the volumes receiving a radiation dose above a threshold are indicated. The target volume was calculated from 
the target mass assuming the liver density used in the Monte Carlo simulations, ρliver = 1.03 g/cm3. Clearly, the volumes 
receiving a radiation dose of at least the desired dose are substantially smaller than the target volume indicated by the 
radiologist. 
In four of five patients, the SPECT-based dose distribution yields a higher maximum dose than the PET-based dose 
distributions. Additionally, Figure 4 shows that in these four patients the SPECT-based volume receiving a certain dose is 
larger than or equal to the volume obtained from PET-based dose calculations for doses > 50Gy.  
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Figure 4 Dose volume histograms for patients 1 to 5 (a to e). The vertical axis shows the volume as a fraction of the total 
target volume, to correct for the differences in target volume.   
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Discussion 
This study shows that dose distributions deducted from technetium-99m MAA SPECT do not necessarily mimic the dose 
distributions obtained from yttrium-90 microspheres PET. 
Although patient benefits for yttrium-90 radioembolization are widely described in literature, improvements of pre-
embolization dosimetry could lead to better tailored therapies. Patient specific treatment planning building on technetium-
99m MAA SPECT-based dosimetry could contribute to better customization of treatments. The better the prediction is made 
using pre-embolization dosimetry, the better the estimate of the optimal injected activity. That way, damage to healthy liver 
tissue can be minimized.  
A number of recent publications describe the feasibility of using technetium-99m MAA SPECT/CT for predictive dosimetry 
[15, 23-25]. More critical publications can also be found, mentioning significant differences comparing predictive SPECT-
based and retrospective PET-based calculated absorbed doses in tumor and normal liver [26], poor correlation between 
yttrium-90 and technetium-99m MAA activity distributions [27], inaccurate prediction of the distribution of yttrium-90 [28] 
as well as overestimation [29] or underestimation [30] of tumorous uptake using predictive dosimetry. This is concordant 
with our results. 
A recent study shows significant differences when comparing SPECT- and PET-based calculated absorbed doses in tumor 
and normal liver [26]. Other literature describes that technetium-99m MAA SPECT/CT-based dosimetry is accurate in HCC 
[23] and that predictive dosimetry is feasible for tumors [15]. In addition, Strigari et al. conclude that technetium-99m MAA 
SPECT images of the abdomen were sufficiently predictive of the yttrium-90 distribution in more than 90% of patients [25].  
Only five patients were included in this study, therefore no quantitative relations between SPECT- and PET-based dosimetry 
were inferred from the obtained data. However, calculations carried out for these five patients suggest that pre-embolization 
dosimetry based on technetium-99m MAA SPECT imaging needs optimization before it can be reliably used in clinical 
practice for the treatment planning. 
The background correction for PET data that was applied only induces a proportional increase in dose calculated based on 
the PET images. Therefore, it does not alter the shape of the dose volume histograms showed in Figure 4. Also, the PET-
based calculated volume receiving a certain dose is smaller (4 patients) or similar (1 patient) after correction, which indicates 
that the applied correction leads to better correspondence between the two calculations. 
Both PET- and SPECT-based calculated dose distributions were smoothed to decrease incidental maxima caused by count 
statistics. After smoothing SPECT-based dose distributions showed higher local maxima than the PET-based images. This 
difference can be attributed to the higher heterogeneity of the technetium-99m MAA distribution. 
A large liver volume receiving a lower radiation dose than scheduled can result in inefficient or insufficient treatment, as a 
relation between tumor dose and response is suggested [13-16]. Because the volume receiving a dose above a certain 
threshold tends to be overestimated when relying on SPECT-based dosimetry, underdosing is a real possibility. 
To better quantify the post-embolization dose distribution, PET images of a higher quality are required. With improvement 
of both pre- and post-treatment dosimetry, a better estimate of the dose response rate is expected. This can additionally be 
used to optimize the patient dose. 
Conclusion 
The inhomogeneity of the distribution of both technetium-99m MAA and yttrium-90 in the target volume results in a 
maximum local radiation dose that is higher than the average target radiation dose and the desired dose.  
Since the relative technetium-99m MAA distribution does not necessarily comply with the distribution of yttrium-90 
microspheres, technetium-99m MAA scans cannot be directly used for prospective radiation dose assessment.   
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